Chinese Pharma Recovers Most Of Contaminated Human Rabies Vaccine
This article was originally published in PharmAsia News
Executive Summary
China's Dalian Jingang-Andi Bio-products says it has recovered nearly all of the 360,200 doses of its human rabies vaccine, 20 percent of the Chinese market, found to be contaminated. The company produced the vaccine last year, but tests in January by the General Administration of Quality Supervision, Inspection and Quarantine, found an illegal nucleic acid adjuvant. The agency had announced earlier that nucleic acid materials could not be used in human vaccines until they undergo clinical trials. No deaths from the vaccine have been reported, a company spokeswoman said. (Click here for more
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.